Table 2.
Predictors of overall survival and recurrence in univariable analysis (N=198)
| OS, months, median (95% CI) | HR (95% CI) | p value | 3-year HDFS, n (%) | HR (95% CI) | p value | |
|---|---|---|---|---|---|---|
| Male sex | 82.0 (63.0–101.0) | — | 0.184 | 68 (34) | — | 0.341 |
| Age | — | 1.00 (0.99–1.02) | 0.963 | — | 0.99 (0.97–1.01) | 0.190 |
| Major comorbidity | 80.7 (54.9–106.5) | — | 0.531 | 62 (31) | — | 0.759 |
| Body mass index | — | 0.97 (0.94–1.01) | 0.177 | — | 0.97 (0.92–1.01) | 0.130 |
| Node-positive primary tumor | 80.7 (55.2–106.2) | — | 0.947 | 37 (19) | — | 0.777 |
| Synchronous CRLM | 80.7 (51.7–109.8) | — | 0.349 | 59 (30) | — | 0.648 |
| Multiple metastases | 67.6 (57.4–77.8) | — | 0.118 | 57 (29) | — | 0.066 |
| CEA >200 | 26.8 ( ) | — | 0.288 | — | — | 0.783 |
| Maximal tumor size | — | 1.08 (1.02–1.15) | 0.014 | — | 1.02 (0.94–1.11) | 0.590 |
| Bilobar disease | 72.5 (61.7–83.4) | — | 0.588 | 45 (23) | — | 0.749 |
| Extrahepatic disease | 36.2 (28.6–43.8) | — | 0.003 | 4 (2) | — | 0.004 |
| Neoadjuvant chemotherapy | 65.3 (56.3–74.4) | — | 0.003 | 58 (29) | — | 0.146 |
| Preoperative PVE | 75.7 (40.8–110.5) | — | 0.799 | 8 (4) | — | 0.016 |
| Steatosis | 98.9 (62.3–135.5) | — | 0.121 | 40 (20) | — | 0.561 |
| Sinusoidal dilation | 75.3 (54.3–96.3) | — | 0.783 | 14 (7) | — | 0.464 |
| Steatohepatitis (grade ≥4) | 68.1 (30.5–105.6) | — | 0.680 | 4 (2) | — | 0.871 |
| Tumor total response >75% | 108.5 (79.4–137.6) | — | 0.119 | 22 (11) | — | 0.584 |
| Tumor fibrosis >40% | — | — | 0.031 | 15 (8) | — | 0.059 |
| Percentage tumor necrosis | — | 0.99 (0.99–1.01) | 0.865 | — | 1.00 (0.99–1.01) | 0.899 |
| Percentage fibrosis | — | 0.99 (0.98–1.00) | 0.146 | — | 0.99 (0.98–1.00) | 0.192 |
| Percentage tumor mucin | — | 0.98 (0.99–1.01) | 0.592 | — | 1.00 (0.98–1.01) | 0.672 |
| FLR correlation | — | 4.76 (0.01–4347) | 0.654 | — | 3.12 (0.00–18546) | 0.797 |
| FLR homogeneity | — | 18.73 (1.29–271.1) | 0.032 | — | 70.24 (3.56–1384) | 0.005 |
| FLR contrast | — | 0.56 (0.31–1.01) | 0.055 | — | 0.50 (0.25–1.00) | 0.050 |
| FLR energy | — | 3.20 (0.93–11.01) | 0.065 | — | 6.36 (1.74–23.29) | 0.005 |
| FLR entropy | — | 0.20 (0.06–0.72) | 0.014 | — | 0.16 (0.04–0.72) | 0.017 |
| Tumor correlation | — | 5.24 (1.58–17.42) | 0.007 | — | 6.02 (1.51–24.03) | 0.011 |
| Tumor homogeneity | — | 8.47 (1.14–63.10) | 0.037 | — | 5.23 (0.46–59.44) | 0.183 |
| Tumor contrast | — | 0.73 (0.58–0.92) | 0.009 | — | 0.78 (0.60–1.03) | 0.078 |
| Tumor energy | — | 1.81 (0.37–8.84) | 0.463 | — | 1.31 (0.17–10.24) | 0.796 |
| Tumor entropy | — | 5.61 (0.51–61.54) | 0.158 | — | 0.54 (0.02–16.03) | 0.722 |
OS overall survival, HDFS hepatic disease-free survival, CRLM colorectal liver metastases, CEA carcinoembryonic antigen, PVE portal vein embolization, FLR future liver remnant